The healing power of gene therapy — Harvard Gazette

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T06:40:13.662Z • Permanent link

Precision and power were on full display at the prestigious National Institutes of Health's (NIH) annual meeting, where Dr. David Liu, the renowned chemist from Harvard University, unveiled a groundbreaking new approach to gene therapy that has left the scientific community abuzz. Liu's team, which includes Dr. William H. Greenberg and Dr. Paul Wender, has developed a novel method for editing genes using a small molecule that can selectively target and modify specific DNA sequences. This breakthrough has significant implications for the treatment of genetic diseases, and could potentially revolutionize the field of gene therapy.

Liu's team has been working on this project for several years, and their research has been supported by a $15 million grant from the NIH. The company, Editas Medicine, which was co-founded by Liu, has already begun testing its technology in human clinical trials. The company's flagship product, CRISPR-Cas9, has already shown promise in treating a range of genetic disorders, including sickle cell anemia and muscular dystrophy.

The NIH meeting also saw the announcement of a new partnership between the NIH and the biotech company, CRISPR Therapeutics, to develop a new gene therapy treatment for Leber congenital amaurosis, a rare and devastating eye disease. The partnership, which is worth up to $500 million, brings together two of the leading players in the gene editing space, and could potentially lead to the development of new and innovative treatments for a range of genetic disorders.

The implications of this breakthrough are far-reaching, and could have a significant impact on the biotech industry as a whole. Companies like CRISPR Therapeutics and Editas Medicine, which are already leading the charge in the field of gene editing, could see their products become even more effective and widely adopted. This could lead to a significant increase in revenue for these companies, and could also drive down the cost of gene therapy treatments, making them more accessible to patients around the world.

The research community is also abuzz with excitement over the potential of this technology, and several leading researchers have already begun exploring its applications in a range of different fields, including regenerative medicine and synthetic biology. The potential for gene editing to revolutionize the treatment of genetic diseases is vast, and could have a significant impact on the lives of millions of people around the world.

The development of gene editing technologies like CRISPR-Cas9 has been a major driver of innovation in the biotech industry over the past decade, and has led to a surge in investment and research in the field. However, the technology is not without its challenges, and several competing approaches are currently being developed. For example, the University of California, Berkeley, has been working on a new gene editing technology that uses a different enzyme to target and modify DNA sequences. While this technology shows promise, it is still in the early stages of development, and it remains to be seen whether it will ultimately prove to be more effective than CRISPR-Cas9.